Piper Sandler Maintains Overweight on Dyne Therapeutics, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $43 to $53.
August 13, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Dyne Therapeutics and raises the price target from $43 to $53.
The increase in the price target from $43 to $53 by a reputable analyst at Piper Sandler is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100